Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:DNLI NYSE:ENOV NASDAQ:ITMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.36-3.0%$12.08$3.98▼$13.90$2.03B1.931.68 million shs2.63 million shsDNLIDenali Therapeutics$12.75-3.3%$14.43$10.57▼$33.33$1.86B1.232.08 million shs4.85 million shsENOVEnovis$32.37-2.4%$29.65$25.47▼$49.83$1.85B1.68974,899 shs1.33 million shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+5.95%+5.78%+28.71%+189.80%DNLIDenali Therapeutics0.00%-10.15%-16.28%-8.21%-58.55%ENOVEnovis0.00%+1.79%+9.97%+7.43%-25.82%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.36-3.0%$12.08$3.98▼$13.90$2.03B1.931.68 million shs2.63 million shsDNLIDenali Therapeutics$12.75-3.3%$14.43$10.57▼$33.33$1.86B1.232.08 million shs4.85 million shsENOVEnovis$32.37-2.4%$29.65$25.47▼$49.83$1.85B1.68974,899 shs1.33 million shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+5.95%+5.78%+28.71%+189.80%DNLIDenali Therapeutics0.00%-10.15%-16.28%-8.21%-58.55%ENOVEnovis0.00%+1.79%+9.97%+7.43%-25.82%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-7.37% DownsideDNLIDenali Therapeutics 3.12Buy$33.50162.75% UpsideENOVEnovis 3.00Buy$51.0057.55% UpsideITMRItamar Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ITMR, ADPT, DNLI, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/8/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $58.008/8/2025ENOVEnovisUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.008/8/2025ENOVEnovisWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$48.00 ➝ $41.008/7/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$57.00 ➝ $49.008/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.007/28/2025DNLIDenali TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$48.00 ➝ $46.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M11.37N/AN/A$1.37 per share9.75DNLIDenali Therapeutics$330.53M5.64N/AN/A$8.53 per share1.49ENOVEnovis$2.11B0.88$19.27 per share1.68$45.10 per share0.72ITMRItamar Medical$41.03M12.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)ENOVEnovis-$825.49M-$14.25N/A10.15N/A-37.80%6.78%3.73%11/5/2025 (Estimated)ITMRItamar MedicalN/A-$1.35N/AN/AN/AN/AN/AN/AN/ALatest ITMR, ADPT, DNLI, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/7/2025Q2 2025ENOVEnovis$0.74$0.79+$0.05-$0.64$555.80 million$564.50 million8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75DNLIDenali Therapeutics0.0110.2710.27ENOVEnovis0.532.251.15ITMRItamar MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%DNLIDenali Therapeutics92.92%ENOVEnovis98.45%ITMRItamar Medical42.19%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%DNLIDenali Therapeutics12.50%ENOVEnovis2.70%ITMRItamar MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableENOVEnovis7,36757.16 million55.62 millionOptionableITMRItamar Medical25716.11 millionN/ANot OptionableITMR, ADPT, DNLI, and ENOV HeadlinesRecent News About These CompaniesItamar Friedman, CEO & Co-Founder of CodiumAI – Interview SeriesMay 11, 2024 | unite.aiUItamar Ben-Gvir Injured in Car Accident – Developing StoryApril 27, 2024 | palestinechronicle.comPNational Security Minister Itamar Ben Gvir's daughter out of hospital following accidentApril 27, 2024 | msn.comsleep apnoeaApril 26, 2024 | pharmaphorum.comPITMR Historical DataOctober 17, 2023 | investing.comRead Your Way Around the WorldAugust 3, 2023 | nytimes.comCPAP versus Oxygen in Obstructive Sleep ApneaMay 19, 2023 | nejm.orgNFind the Best Medical SchoolsMay 14, 2023 | usnews.comItamar Ben-Gvir: 'Last year I saw suffering in Meron'April 29, 2023 | israelnationalnews.comIPolice chief said to order senior cops to avoid direct contact with Itamar Ben GvirMarch 15, 2023 | timesofisrael.comT'You ruined the police,' Tel Aviv district commander tells Israel Police chiefMarch 12, 2023 | jpost.comJBritish Foreign Secretary: We have no plans to engage with Ben GvirFebruary 26, 2023 | israelnationalnews.comIBen Gvir: This isn't what we signed up forFebruary 17, 2023 | israelnationalnews.comIBen-Gvir proposes ‘Defensive Shield 2’ operation as security cabinet to meetFebruary 13, 2023 | jpost.comJ'Heil Kahane': Meretz ex-chief under fire for tweet on Ben-GvirJanuary 27, 2023 | israelnationalnews.comIMansour Abbas: Ben Gvir thinks he is a superman who can solve all the problemsJanuary 17, 2023 | israelnationalnews.comIPolice spokesman: 'Ben-Gvir's appointment has deterrent effect on Arab sector'January 15, 2023 | israelnationalnews.comIYoung Settlement Forum to Ministers: "Now it's up to you"January 12, 2023 | israelnationalnews.comIItamar Ben-Gvir bans the Palestinian flagJanuary 11, 2023 | albawaba.comA'More than Itamar Ben-Gvir, it is the right-wing drift of public opinion in Israel that is worrying'January 11, 2023 | lemonde.frLNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITMR, ADPT, DNLI, and ENOV Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$13.36 -0.41 (-2.98%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$13.56 +0.20 (+1.46%) As of 09/19/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Denali Therapeutics NASDAQ:DNLI$12.75 -0.43 (-3.26%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$13.17 +0.42 (+3.29%) As of 09/19/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Enovis NYSE:ENOV$32.37 -0.80 (-2.41%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$32.37 0.00 (0.00%) As of 09/19/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Itamar Medical NASDAQ:ITMRItamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
